UY28243A1 - QUINOLINE AND QUNOXALINE COMPOUNDS - Google Patents
QUINOLINE AND QUNOXALINE COMPOUNDSInfo
- Publication number
- UY28243A1 UY28243A1 UY28243A UY28243A UY28243A1 UY 28243 A1 UY28243 A1 UY 28243A1 UY 28243 A UY28243 A UY 28243A UY 28243 A UY28243 A UY 28243A UY 28243 A1 UY28243 A1 UY 28243A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- cholesterol
- levels
- quinoline
- triglycerides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Compuestos de quinolina y quinoxalina, composiciones farmacéuticas que contienen tales compuestos y el uso de tales compuestos para aumentar ciertos niveles de lípidos en el plasma, incluyendo la lipoproteína de alta densidad del colesterol y para reducir otros niveles de lípidos en plasma, tales como colesterol LDL y triglicéridos, y por consiguiente, para tratar enfermedades que se ven afectadas por los niveles bajos de colesterol HDL y/o niveles altos de colesterol-LDL y triglicéridos, tales como aterosclerosis y enfermedades cardiovasculares en ciertos mamíferos, incluyendo seres humanos.Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to increase certain levels of plasma lipids, including high-density lipoprotein cholesterol and to reduce other plasma lipid levels, such as LDL cholesterol and triglycerides, and therefore, to treat diseases that are affected by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in certain mammals, including humans.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45827403P | 2003-03-28 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28243A1 true UY28243A1 (en) | 2004-11-08 |
Family
ID=33098266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28243A UY28243A1 (en) | 2003-03-28 | 2004-03-25 | QUINOLINE AND QUNOXALINE COMPOUNDS |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1622872A1 (en) |
JP (1) | JP2006521344A (en) |
KR (1) | KR100729883B1 (en) |
CN (1) | CN1795177A (en) |
AR (1) | AR044507A1 (en) |
AU (1) | AU2004224082A1 (en) |
BR (1) | BRPI0408897A (en) |
CA (1) | CA2520405A1 (en) |
CL (1) | CL2004000639A1 (en) |
EA (1) | EA200501376A1 (en) |
EC (1) | ECSP056040A (en) |
GT (1) | GT200400050A (en) |
HR (1) | HRP20050859A2 (en) |
MA (1) | MA27828A1 (en) |
MX (1) | MXPA05010456A (en) |
NL (1) | NL1025839C2 (en) |
NO (1) | NO20054989L (en) |
OA (1) | OA13153A (en) |
PA (1) | PA8598901A1 (en) |
PE (1) | PE20050389A1 (en) |
TN (1) | TNSN05243A1 (en) |
TW (1) | TWI285641B (en) |
UY (1) | UY28243A1 (en) |
WO (1) | WO2004085401A1 (en) |
ZA (1) | ZA200507819B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004065380A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
DK2910551T3 (en) | 2003-04-11 | 2017-05-15 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds and their use in nonsense suppression and the treatment of disease |
JP4920410B2 (en) | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Fused aryl and heteroaryl derivatives as metabolic modulators and prevention and treatment of metabolic-related disorders |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
AR051780A1 (en) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | FUSIONED RING COMPOUNDS CONTAINING NITROGEN AND USING THEMSELVES |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
ZA200707498B (en) * | 2005-02-24 | 2008-11-26 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7888376B2 (en) * | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
UY30118A1 (en) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDE COMPUTER |
US7745477B2 (en) * | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
US8232403B2 (en) | 2006-05-10 | 2012-07-31 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
JP4108729B2 (en) * | 2006-05-26 | 2008-06-25 | 日本たばこ産業株式会社 | Nitrogen-containing fused ring compound-containing pharmaceutical composition |
US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
JP2010509388A (en) * | 2006-11-15 | 2010-03-25 | ノバルティス アーゲー | Organic compounds |
JP4846769B2 (en) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
EP3311813B1 (en) | 2007-08-27 | 2019-08-07 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
CN102203065B (en) * | 2008-10-29 | 2014-07-09 | 霍夫曼-拉罗奇有限公司 | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
PE20131371A1 (en) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | GPR119 RECEPTOR MODULATORS AND THE TREATMENT OF RELATED DISORDERS |
CN105934246B (en) | 2013-11-18 | 2019-10-22 | 福马疗法公司 | Tetrahydroquinoline constituent as BET bromine domain inhibitor |
CN106029076B (en) * | 2013-11-18 | 2019-06-07 | 福马疗法公司 | Benzo piperazine composition as BET bromine domain inhibitor |
CA3174516A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
KR20230151072A (en) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | Methods of treating conditions related to the s1p1 receptor |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
MX2018005361A (en) | 2015-10-30 | 2018-06-07 | Ptc Therapeutics Inc | Methods for treating epilepsy. |
MA47504A (en) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS |
CN110452183B (en) * | 2019-09-04 | 2023-03-14 | 中国科学院上海有机化学研究所 | Preparation method of chiral heterocyclic compound |
CN111440162A (en) * | 2020-04-01 | 2020-07-24 | 邱曲真 | Thiazole dihydronaphthalene derivative and application thereof in metabolic diseases |
CN114656406B (en) * | 2022-01-25 | 2023-09-05 | 阿里生物新材料(常州)有限公司 | Synthesis method of 2-fluoropyrimidine-4-carboxylic acid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE351464C (en) * | 1917-12-18 | 1922-04-07 | Chemische Werke Grenzach Aktie | Process for the preparation of derivatives of a hydrogenated 2-phenylquinoline-4-carboxylic acid |
DK0800519T3 (en) * | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroid receptor modulator compounds and methods |
EP0936866A4 (en) * | 1996-10-28 | 2001-04-11 | Dept Of The Army Us Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
AU2717899A (en) * | 1998-01-26 | 1999-08-09 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
CO5271716A1 (en) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED |
-
2004
- 2004-03-15 OA OA1200500269A patent/OA13153A/en unknown
- 2004-03-15 EA EA200501376A patent/EA200501376A1/en unknown
- 2004-03-15 KR KR1020057018383A patent/KR100729883B1/en not_active IP Right Cessation
- 2004-03-15 MX MXPA05010456A patent/MXPA05010456A/en unknown
- 2004-03-15 CN CNA2004800146455A patent/CN1795177A/en active Pending
- 2004-03-15 BR BRPI0408897-2A patent/BRPI0408897A/en not_active IP Right Cessation
- 2004-03-15 CA CA002520405A patent/CA2520405A1/en not_active Abandoned
- 2004-03-15 JP JP2006506369A patent/JP2006521344A/en active Pending
- 2004-03-15 AU AU2004224082A patent/AU2004224082A1/en not_active Abandoned
- 2004-03-15 EP EP04720668A patent/EP1622872A1/en not_active Withdrawn
- 2004-03-15 WO PCT/IB2004/000836 patent/WO2004085401A1/en active Application Filing
- 2004-03-23 GT GT200400050A patent/GT200400050A/en unknown
- 2004-03-25 CL CL200400639A patent/CL2004000639A1/en unknown
- 2004-03-25 UY UY28243A patent/UY28243A1/en not_active Application Discontinuation
- 2004-03-26 PE PE2004000323A patent/PE20050389A1/en not_active Application Discontinuation
- 2004-03-26 TW TW093108314A patent/TWI285641B/en not_active IP Right Cessation
- 2004-03-26 AR ARP040101024A patent/AR044507A1/en unknown
- 2004-03-26 NL NL1025839A patent/NL1025839C2/en not_active IP Right Cessation
- 2004-03-26 PA PA20048598901A patent/PA8598901A1/en unknown
-
2005
- 2005-09-26 EC EC2005006040A patent/ECSP056040A/en unknown
- 2005-09-27 ZA ZA200507819A patent/ZA200507819B/en unknown
- 2005-09-28 HR HR20050859A patent/HRP20050859A2/en not_active Application Discontinuation
- 2005-09-28 TN TNP2005000243A patent/TNSN05243A1/en unknown
- 2005-09-28 MA MA28519A patent/MA27828A1/en unknown
- 2005-10-26 NO NO20054989A patent/NO20054989L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR044507A1 (en) | 2005-09-14 |
NL1025839C2 (en) | 2006-09-06 |
EP1622872A1 (en) | 2006-02-08 |
NL1025839A1 (en) | 2004-09-30 |
EA200501376A1 (en) | 2006-04-28 |
MA27828A1 (en) | 2006-04-03 |
TNSN05243A1 (en) | 2007-06-11 |
TW200508222A (en) | 2005-03-01 |
GT200400050A (en) | 2005-03-02 |
WO2004085401A8 (en) | 2005-12-01 |
PA8598901A1 (en) | 2004-11-26 |
KR100729883B1 (en) | 2007-06-18 |
CN1795177A (en) | 2006-06-28 |
CA2520405A1 (en) | 2004-10-07 |
MXPA05010456A (en) | 2006-03-21 |
HRP20050859A2 (en) | 2006-02-28 |
KR20050115938A (en) | 2005-12-08 |
WO2004085401A1 (en) | 2004-10-07 |
AU2004224082A1 (en) | 2004-10-07 |
ECSP056040A (en) | 2006-01-27 |
OA13153A (en) | 2006-12-13 |
BRPI0408897A (en) | 2006-04-18 |
PE20050389A1 (en) | 2005-05-30 |
TWI285641B (en) | 2007-08-21 |
NO20054989L (en) | 2005-12-16 |
CL2004000639A1 (en) | 2005-02-04 |
NO20054989D0 (en) | 2005-10-26 |
JP2006521344A (en) | 2006-09-21 |
ZA200507819B (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28243A1 (en) | QUINOLINE AND QUNOXALINE COMPOUNDS | |
UY29222A1 (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINA | |
DOP2007000044A (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
CR6310A (en) | 1,2,3,4-TETRAHYDROQUINOLINS 2-SUBSTITUTED 4-CARBOXYAMIN REPLACED | |
SV2003000886A (en) | PPAR AGONISTS REF. PC11023AADO / BB | |
PA8481201A1 (en) | 1,2,3,4-TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO | |
CR9012A (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | |
UY28097A1 (en) | PPAR ACTIVATORS | |
CL2012001124A1 (en) | Pharmaceutical composition comprising a concentrated therapeutic extract, comprising phospholipids in a concentration of 60 to 99% and used to treat cardiovascular diseases, reduce triglyceride levels, reduce LDL cholesterol and increase HDL cholesterol. | |
UY29124A1 (en) | QUINOLINE COMPOUNDS | |
ECSP088729A (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
BRPI0607839A2 (en) | substituted 1,1,1-trifluoro-3 - [(benzyl) - (pyrimidin-2-yl) amino] propan-2-ol compounds | |
DOP2004000863A (en) | QUINOLINE AND QUINOXALINE COMPOUNDS | |
DOP2002000327A (en) | PPAR AGONISTS | |
UY27168A1 (en) | PPAR AGONISTS | |
DOP2005000179A (en) | QUINOLINE COMPOUND | |
DOP2005000238A (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINA | |
ECSP088730A (en) | DIBENCILAMINE DERIVATIVES AS CETP INHIBITORS | |
UY27158A1 (en) | PPAR COMPOUNDS | |
DOP2003000762A (en) | PPAR ACTIVATORS | |
DOP2002000331A (en) | PPAR COMPOUND | |
UY29123A1 (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | |
CU20080164A7 (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
DOP2005000182A (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3-TETRAHYDROQUINOLINE COMPOUNDS | |
ECSP993134A (en) | 1,2,3,4- TETRAHIDROQUINOLINAS -2-SUBSTITUTED 4- CARBOXIAMINO SUBSTITUTED |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150520 |